Highlights Neurotech International Limited

Equities

NTI

AU000000NTI9

Delayed Australian S.E. Other stock markets 11:06:21 2024-05-30 pm EDT			5-day change	1st Jan Change
0.072 ^AUD	0.00%		-2.70%	+4.35%

Apr. 17	Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	MT
Apr. 17	Neurotech International Completes AU$10 Million Capital Raise	MT

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Neurotech's Phase II/III NTIASD2 Clinical Trial for Children with Autism Meets Primary Endpoint	Apr. 17	MT
Neurotech International Concludes Phase II/III NTIASD2 Trial for Children with Autism	Apr. 09	MT
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2023	Feb. 26	CI
Neurotech International Secures Approval to Advance Cerebral Palsy Trial; Shares Rise 6%	Jan. 28	MT
Neurotech International Limited Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Neurotech International Secures Ethics Approval for Clinical Trial of Neurological Medication	23-07-10	MT
Neurotech International Secures Ethics Approval to Extend Use of Medication in Pediatric Trial	23-05-30	MT
Neurotech International Plans to Launch Phase Two Rett Syndrome Trial	23-03-20	MT
Neurotech International Limited Announces the Launch of A New Clinical Program in Rett Syndrome, Commencement of A Phase II Clinical Trial Investigating the Use of NTI164 in Female Patients	23-03-19	CI
Neurotech International Limited Announces the Final Clinical Results from Eleven Paediatric Autism Spectrum Disorder Patients, Following Daily Treatment of NTI164 over 52 Week Period	23-03-16	CI
Neurotech International Limited Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-28	CI
Neurotech International Limited Announces First Patient Treated in Phase I/II PANDAS/PANS Trial	23-02-15	CI
Neurotech International Secures Ethics Approval to Extend Phase 1/2 Autism Trial	23-02-14	MT
Neurotech International Limited Announces Approval for Additional Phase I/II ASD Trial Extension	23-02-13	CI
Neurotech International Limited Receives HREC Approval for Phase I/II PANDAS/PANS Clinical Trial	23-01-26	CI
Neurotech International Schedules US FDA Meeting for Autism Spectrum Drug	23-01-19	MT
Neurotech International Limited Announces Grant of FDA Pre-IND Meeting for NTI164 in ASD	23-01-18	CI
Neurotech International Limited Announces Commencement of Patient Randomisation and First Patient Successfully Treats Under New Phase II/III NTIASD2 Clinical Trial for Children with Autism Spectrum Disorder	22-12-18	CI
Neurotech International Limited Reports Further Significant Clinical Improvement at 20 Weeks for Paediatric Autism Patients Treated with NTI164	22-10-25	CI
Neurotech International Limited Announces New Phase I/II Clinical Trial in Children with PANDAS/PANS	22-10-16	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Neurotech International Limited

Equities

NTI

AU000000NTI9

Highlights

Filters